Ascentage Pharma Group Internat (AAPG)Healthcare | Biotechnology | Suzhou, China | NasdaqGM
26.36 USD
-1.04
(-3.796%) ⇩
(April 20, 2026, 4 p.m.
EDT)
Short-term: ☆☆☆☆☆ | Long-term: ★★★☆☆ | Dividends: ☆☆☆☆☆ |
Hot Take | April 18, 2026, 10:10 p.m. EDT
Neutral-low momentum with clear value-trap risks due to losses, recent gains dampened by model bearish signal, a turn-around candidate needing better delivery in next quarter. |
| Model | MAE |
|---|---|
| AutoARIMA ✓ | 0.063058 |
| MSTL | 0.066984 |
| AutoETS | 0.069154 |
| AutoTheta | 0.091173 |
Forecast horizon: 45 days | Selected: AutoARIMA
| Forecast Reliability | |
|---|---|
| Score | 46% |
| H-stat | 7.21 |
| Ljung-Box p | 0.000 |
| Jarque-Bera p | 0.095 |
| Excess Kurtosis | -0.49 |
| Attribute | Value |
|---|---|
| Sector | Healthcare |
| Debt to Equity Ratio | 148.381 |
| Revenue per Share | 6.448 |
| Market Cap | 2,522,700,032 |
| Forward P/E | -22.06 |
| Beta | 0.82 |
| Profit Margins | -216.47% |
| Website | https://www.ascentage.cn |
| Attribute | Value |
|---|---|
| 52 Week Change | 0.22037041 |
| Address1 | Suzhou Industrial Park |
| Address2 | 68 Xinqing Road |
| All Time High | 48.45 |
| All Time Low | 16.5 |
| Ask | 23.14 |
| Ask Size | 1 |
| Average Analyst Rating | 1.3 - Strong Buy |
| Average Daily Volume10 Day | 1,440 |
| Average Daily Volume3 Month | 2,737 |
| Average Volume | 2,737 |
| Average Volume10Days | 1,440 |
| Beta | 0.815 |
| Bid | 27.0 |
| Bid Size | 1 |
| Book Value | 2.0960648 |
| City | Suzhou |
| Compensation As Of Epoch Date | 1,735,603,200 |
| Country | China |
| Crypto Tradeable | 0 |
| Currency | USD |
| Current Price | 26.36 |
| Current Ratio | 1.792 |
| Custom Price Alert Confidence | HIGH |
| Date Short Interest | 1,774,915,200 |
| Day High | 26.395 |
| Day Low | 26.35 |
| Debt To Equity | 148.381 |
| Display Name | Ascentage Pharma |
| Earnings Call Timestamp End | 1,774,555,200 |
| Earnings Call Timestamp Start | 1,774,555,200 |
| Earnings Timestamp | 1,774,468,800 |
| Earnings Timestamp End | 1,774,468,800 |
| Earnings Timestamp Start | 1,774,468,800 |
| Ebitda | -1,132,252,032 |
| Ebitda Margins | -1.97215 |
| Enterprise To Ebitda | -8.205 |
| Enterprise To Revenue | 16.182 |
| Enterprise Value | 9,290,242,048 |
| Eps Current Year | -1.52019 |
| Eps Forward | -1.195 |
| Eps Trailing Twelve Months | -2.05 |
| Esg Populated | 0 |
| Exchange | NGM |
| Exchange Data Delayed By | 0 |
| Exchange Timezone Name | America/New_York |
| Exchange Timezone Short Name | EDT |
| Fifty Day Average | 24.33892 |
| Fifty Day Average Change | 2.02108 |
| Fifty Day Average Change Percent | 0.083039016 |
| Fifty Two Week Change Percent | 22.03704 |
| Fifty Two Week High | 48.45 |
| Fifty Two Week High Change | -22.09 |
| Fifty Two Week High Change Percent | -0.45593396 |
| Fifty Two Week Low | 19.11 |
| Fifty Two Week Low Change | 7.25 |
| Fifty Two Week Low Change Percent | 0.37938252 |
| Fifty Two Week Range | 19.11 - 48.45 |
| Financial Currency | CNY |
| First Trade Date Milliseconds | 1,737,729,000,000 |
| Float Shares | 283,947,953 |
| Forward Eps | -1.195 |
| Forward P E | -22.058577 |
| Full Exchange Name | NasdaqGM |
| Full Time Employees | 767 |
| Gmt Off Set Milliseconds | -14,400,000 |
| Gross Margins | 0.91476 |
| Gross Profits | 525,182,016 |
| Has Pre Post Market Data | 1 |
| Held Percent Insiders | 0.0 |
| Held Percent Institutions | 0.00075999997 |
| Implied Shares Outstanding | 95,701,822 |
| Industry | Biotechnology |
| Industry Disp | Biotechnology |
| Industry Key | biotechnology |
| Is Earnings Date Estimate | 0 |
| Language | en-US |
| Last Fiscal Year End | 1,767,139,200 |
| Long Business Summary | Ascentage Pharma Group International, a clinical-stage biotechnology company, develops therapies for cancers, chronic hepatitis B virus (HBV), and age-related diseases in Mainland China. The company's primary product candidate is HQP1351, a BCR-ABL inhibitor targeting BCR-ABL1 mutants, including those with the T315I mutation. It also develops APG-2575, an oral administered Bcl-2 selective inhibitor for hematologic malignancies and solid tumors; APG-115, an oral small molecule inhibitor of the MDM2-p53 protein-protein interactions to treat solid tumors and hematological malignancies; and APG-1252, a small molecule drug to restore apoptosis through dual inhibition of the Bcl-2 and Bcl-xL proteins for the treatment of small-cell lung cancer, non-small cell lung cancer, neuroendocrine tumor, and non-Hodgkin's lymphoma. In addition, the company is developing APG-1387, a small-molecule inhibitor of apoptosis proteins for advanced solid tumors and chronic HBV infection; APG-2449, an oral inhibitor of FAK, ROS1, and ALK kinases; APG-5918, an orally available and selective embryonic ectoderm development inhibitor. In addition, it is involved in medical research and development; clinical development; clinical trials operations; venture capital investment; rental of buildings; and provision of science and technology promotion services. The company has collaboration relationships with biotechnology and pharmaceutical companies; and research institutions. Ascentage Pharma Group International was founded in 2009 and is headquartered in Suzhou, China. |
| Market | us_market |
| Market Cap | 2,522,700,032 |
| Market State | PRE |
| Max Age | 86,400 |
| Message Board Id | finmb_620569787 |
| Most Recent Quarter | 1,767,139,200 |
| Net Income To Common | -1,242,769,024 |
| Next Fiscal Year End | 1,798,675,200 |
| Non Diluted Market Cap | 2,452,586,028 |
| Number Of Analyst Opinions | 7 |
| Open | 26.35 |
| Operating Margins | -1.9335 |
| Payout Ratio | 0.0 |
| Phone | 86 512 8555 7777 |
| Previous Close | 27.4 |
| Price Eps Current Year | -17.33994 |
| Price Hint | 2 |
| Price To Book | 12.575948 |
| Price To Sales Trailing12 Months | 4.394029 |
| Profit Margins | -2.16465 |
| Quick Ratio | 1.657 |
| Quote Source Name | Nasdaq Real Time Price |
| Quote Type | EQUITY |
| Recommendation Key | strong_buy |
| Recommendation Mean | 1.28571 |
| Region | US |
| Regular Market Change | -1.039999 |
| Regular Market Change Percent | -3.7956166 |
| Regular Market Day High | 26.395 |
| Regular Market Day Low | 26.35 |
| Regular Market Day Range | 26.35 - 26.395 |
| Regular Market Open | 26.35 |
| Regular Market Previous Close | 27.4 |
| Regular Market Price | 26.36 |
| Regular Market Time | 1,776,715,200 |
| Regular Market Volume | 1,773 |
| Return On Assets | -0.23023 |
| Return On Equity | -1.54564 |
| Revenue Growth | 1.17 |
| Revenue Per Share | 6.448 |
| Sand P52 Week Change | 0.34445214 |
| Sector | Healthcare |
| Sector Disp | Healthcare |
| Sector Key | healthcare |
| Shares Outstanding | 93,330,423 |
| Shares Percent Shares Out | 0.0 |
| Shares Short | 1,470 |
| Shares Short Previous Month Date | 1,772,150,400 |
| Shares Short Prior Month | 147 |
| Short Name | Ascentage Pharma Group Internat |
| Short Percent Of Float | 0.0 |
| Short Ratio | 0.42 |
| Source Interval | 15 |
| Symbol | AAPG |
| Target High Price | 55.0 |
| Target Low Price | 45.0 |
| Target Mean Price | 49.0 |
| Target Median Price | 48.0 |
| Total Cash | 2,470,085,120 |
| Total Cash Per Share | 6.664 |
| Total Debt | 1,979,719,040 |
| Total Revenue | 574,120,000 |
| Tradeable | 0 |
| Trailing Annual Dividend Rate | 0.0 |
| Trailing Annual Dividend Yield | 0.0 |
| Trailing Eps | -2.05 |
| Trailing Peg Ratio | None |
| Triggerable | 1 |
| Two Hundred Day Average | 32.24177 |
| Two Hundred Day Average Change | -5.881771 |
| Two Hundred Day Average Change Percent | -0.18242705 |
| Type Disp | Equity |
| Volume | 1,773 |
| Website | https://www.ascentage.cn |
| Zip | 215,000 |